In Regard to Bovi et  al.

I read with great interest the article titled “Pulsed reduced dose rate radiation therapy in conjunction with bevacizumab significantly extends survival over bevacizumab alone in recurrent high-grade glioma” by Bovi et al.1 This retrospective report concludes that pulsed reduced dose-rate radiation therapy (PRDR-RT) plus bevacizumab provid es significant progression free survival and overall survival advantages compared with bevacizumab alone. As a user of PRDR-RT, not only is this publication an important step forward in the evaluation of novel fractionation schemes in brain tumors, but also I agree with the authors in that PRDR-RT r andomized trials should be conducted.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Comments Source Type: research